NucleoBio’s investigative therapy Prostreat was seen to be better at preventing the growth and spread of metastatic castration-resistant prostate cancer than currently available hormone therapies, a mouse study showed. The treatment was effective even in cells with a variant of the androgen receptor that renders them resistant to treatment, setting the basis for the development of Prostreat for the most aggressive form of prostate cancer. The company is now planning to advance the therapy candidate into clinical trials later this year. The findings were recently presented at the 25th Biennial Congress of the European Association for Cancer Research, held June 30-July 3 in Amsterdam. The poster was titled, “Two novel synthetic analogues of miR-1207–3 p, NB5 and NB1207, target AR-V7 and c-MYC and demonstrate in vivo therapeutic efficacy in metastatic castrate-resistant prostate cancer (mCRPC).” Mutations in a region of chromosome 8 are known to increase a patient's susceptibility to prostate cancer. Researchers recently discovered that this happens because the mutations reduce the levels of a small RNA molecule, called miR-1207-3p, which leads to an increase in androgen receptor production. Researchers set out to investigate whether miR-1207-3p could be used as a therapeutic approach for prostate cancer. The team was led by Olorunseun Ogunwobi, an MD and PhD, and investigator at Hunter College of The City University of New York (CUNY) and co-founder of NucleoBio. Investigators first examined the levels of miR-1207-3p in prostate cancer tissue and compared them to those of healthy prostate tissue and benign prostatic hyperplasia (BPH) tissue samples. They found that miR-1207-3p was significantly reduced in prostate cancer samples.